Predicting how HIV-1 may resist treatments to personalize care for patients
Official title: Predicting HIV-1 escape from therapeutics in vitro and in vivo - toward personalizing medicine for people living with HIV
Funded at University of Iowa · NIH-11056762 · Data updated 2026-11-12
This study is looking at how changes in the HIV-1 virus can make it harder for certain treatments to work, so we can better predict which patients might need different therapies to improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | April 21, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $567,701 |
| NIH project number | 5R01AI170205-03 |
| Project ID | NIH-11056762 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are starting or currently undergoing antiretroviral therapy.
✕Less likely to help
Patients who are not living with HIV or those who have already developed significant resistance to all available antiretroviral therapies may not benefit from this research.
What this research studies
This research investigates how mutations in the HIV-1 virus can lead to resistance against antiretroviral therapies. By analyzing the genetic sequences of the virus, the study aims to predict which patients are likely to develop resistance to specific treatments. The approach involves using advanced algorithms to forecast changes in the virus's proteins before treatment begins, allowing for more tailored therapeutic strategies. Ultimately, the goal is to improve treatment outcomes for individuals living with HIV by personalizing their care based on their unique viral characteristics.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for people living with HIV, reducing the risk of therapy resistance.
How similar studies have gone: Previous research has shown promise in using genetic sequencing to predict viral resistance, indicating that this approach could lead to significant advancements in personalized HIV treatment.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Haim, Hillel — University of Iowa
- Study coordinator: Haim, Hillel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.